Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide with Durvalumab, Carboplatin, and Etoposide for First-line Treatment of Extensive Stage Small-Cell Lung Cancer

Inclusion Criteria

• Must provide informed consent before starting any study-related activities.
• Must be 18 years or older, or the legal age in your country if it's higher than 18.
• Must have a confirmed diagnosis of extensive stage small-cell lung cancer (ES-SCLC) based on specific medical criteria.
• Must have measurable cancer as defined by standard criteria.
• Must be suitable to receive the combination of carboplatin, etoposide, and durvalumab as the first treatment option, according to the doctor's assessment.
• Must have a life expectancy of at least 12 weeks.

Exclusion Criteria

• Cannot have had any other cancer in the last 2 years.
• Cannot have cancer that has spread to the brain or the membranes surrounding the brain and spinal cord.
• Cannot have had severe or life-threatening reactions to immune therapy in the past.
• Cannot have had a stroke or mini-stroke within 6 months before starting the study treatment.
• Cannot have active autoimmune or inflammatory diseases.
• Cannot have active HIV or Hepatitis B or C infections.
• Cannot have lung diseases like interstitial lung disease or non-infectious pneumonitis.
• Cannot have had a solid organ transplant.
• Cannot have had a heart attack or severe heart failure within 6 months before starting the study treatment.